{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T12:47:34Z","timestamp":1775306854483,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Homocysteine (Hcy) is considered a risk factor for cardiovascular disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To explore the long-term prognostic value of Hcy in patients with stable coronary artery disease (CAD) in the era of statins.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 876 consecutive patients with stable CAD were recruited and followed up for a median of 6.1\u2009years. Lipids and Hcy levels were measured at baseline. Primary endpoints were cardiac death and secondary endpoints were hospitalizations for acute coronary syndrome, myocardial revascularization, arrhythmic event or ischemic stroke.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Follow-up data were obtained from 842 patients of whom 70 had a cardiac death (8.3%), while 258 (30.6%) met the secondary endpoints. Seven hundred four patients (83.6%) were on statins. In univariate Cox regression analysis Hcy predicted the occurrence of cardiac death [hazard ratio: 1.030; 95% confidence interval (CI): 1.018\u20131.042, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001] but not the occurrence of secondary endpoints (hazard ratio: 1.010; 95% CI: 0.999\u20131.020, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.081). Hcy remained an independent predictor of cardiac death after adjustment for conventional risk factors, ejection fraction and statin use (hazard ratio: 1.030; 95% CI: 1.017\u20131.044, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001). Patients in the highest tertile of Hcy levels (&gt;14.1\u2009\u03bcmol\/L) had three times higher risk of cardiac death compared with patients in the lowest tertile (&lt;10.3\u2009\u03bcmol\/L) (hazard ratio\u2009=\u20093.036, CI: 1.983\u20134.649, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Hcy is an independent predictor of cardiac death in patients with stable CAD in the era of statins.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000000800","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T15:43:10Z","timestamp":1571067790000},"page":"152-156","source":"Crossref","is-referenced-by-count":14,"title":["Homocysteine is an independent predictor of long-term cardiac mortality in patients with stable coronary artery disease in the era of statins"],"prefix":"10.1097","volume":"31","author":[{"given":"Loukianos S.","family":"Rallidis","sequence":"first","affiliation":[{"name":"Second Department of Cardiology, University General Hospital, \u2018Attikon\u2019"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kosmas","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, University General Hospital, \u2018Attikon\u2019"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taxiarchoula","family":"Rallidi","sequence":"additional","affiliation":[{"name":"School of Dentistry, National and Kapodistrian University of Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Pavlakis","sequence":"additional","affiliation":[{"name":"KAT General Hospital of Attica, Athens"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela","family":"Kiouri","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, University General Hospital, \u2018Attikon\u2019"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Zolindaki","sequence":"additional","affiliation":[{"name":"Biochemistry Laboratory, General Hospital of Nikea, Piraeus, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230924","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin.","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"R2-20230924","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1155\/2013\/563717","article-title":"Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.","volume":"35","author":"Cai","year":"2013","journal-title":"Dis Markers"},{"key":"R3-20230924","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.5603\/KP.2015.0229","article-title":"Homocysteine\u2013is it still an important risk factor for cardiovascular disease?.","volume":"73","author":"Cybulska","year":"2015","journal-title":"Kardiol Pol"},{"key":"R4-20230924","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/157340209788166940","article-title":"Hyperhomocysteinemia and endothelial dysfunction.","volume":"5","author":"Cheng","year":"2009","journal-title":"Curr Hypertens Rev"},{"key":"R5-20230924","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1160\/TH05-05-0313","article-title":"Homocysteine and thrombosis: from basic science to clinical evidence.","volume":"94","author":"Undas","year":"2005","journal-title":"Thromb Haemost"},{"key":"R6-20230924","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.2147\/CIA.S91652","article-title":"Hyperhomocysteinemia is an independent predictor of long-term clinical outcomes in Chinese octogenarians with acute coronary syndrome.","volume":"10","author":"Fu","year":"2015","journal-title":"Clin Interv Aging"},{"key":"R7-20230924","doi-asserted-by":"crossref","first-page":"e1464","DOI":"10.1097\/MJT.0000000000000130","article-title":"Correlation between hyperhomocysteinemia and outcomes of patients with acute myocardial infarction.","volume":"23","author":"Ma","year":"2016","journal-title":"Am J Ther"},{"key":"R8-20230924","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/archinte.160.12.1834","article-title":"Serum homocysteine concentration as an indicator of survival in patients with acute coronary syndromes.","volume":"160","author":"Omland","year":"2000","journal-title":"Arch Intern Med"},{"key":"R9-20230924","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM199707243370403","article-title":"Plasma homocysteine levels and mortality in patients with coronary artery disease.","volume":"337","author":"Nyg\u00e5rd","year":"1997","journal-title":"N Engl J Med"},{"key":"R10-20230924","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1046\/j.1365-2796.2003.01096.x","article-title":"Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: a 10-year follow-up study.","volume":"253","author":"Retterstol","year":"2003","journal-title":"J Intern Med"},{"key":"R11-20230924","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jacc.2012.06.057","article-title":"Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up.","volume":"60","author":"Rallidis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R12-20230924","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1631\/jzus.B1400183","article-title":"Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies.","volume":"16","author":"Peng","year":"2015","journal-title":"J Zhejiang Univ Sci B"},{"key":"R13-20230924","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jacc.2011.05.028","article-title":"Homocysteine and reclassification of cardiovascular disease risk.","volume":"58","author":"Veeranna","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R14-20230924","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2891-14-6","article-title":"Role of homocysteine in the development of cardiovascular disease.","volume":"14","author":"Ganguly","year":"2015","journal-title":"Nutr J"},{"key":"R15-20230924","first-page":"CD006612","article-title":"Homocysteine-lowering interventions for preventing cardiovascular events.","volume":"8","author":"Mart\u00ed-Carvajal","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20230924","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.med.60.041807.123308","article-title":"The treatment of hyperhomocysteinemia.","volume":"60","author":"Maron","year":"2009","journal-title":"Annu Rev Med"},{"key":"R17-20230924","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10545-010-9151-1","article-title":"The homocysteine controversy.","volume":"34","author":"Smulders","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"R18-20230924","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.CIR.102.11.1227","article-title":"Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease.","volume":"102","author":"Anderson","year":"2000","journal-title":"Circulation"},{"key":"R19-20230924","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0735-1097(02)02267-2","article-title":"The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: the Global Evaluation of New Events and Restenosis After Stent Implantation Study.","volume":"40","author":"Zairis","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R20-20230924","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1139\/cjpp-2018-0112","article-title":"Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems.","volume":"96","author":"Djuric","year":"2018","journal-title":"Can J Physiol Pharmacol"},{"key":"R21-20230924","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3390\/ijms20040867","article-title":"The contribution of homocysteine metabolism disruption to endothelial dysfunction: state-of-the-art.","volume":"20","author":"Esse","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R22-20230924","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-017-02401-7","article-title":"Homocysteine directly interacts and activates the angiotensin II type I receptor to aggravate vascular injury.","volume":"9","author":"Li","year":"2018","journal-title":"Nat Commun"},{"key":"R23-20230924","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12272-018-1016-4","article-title":"Causes of hyperhomocysteinemia and its pathological significance.","volume":"41","author":"Kim","year":"2018","journal-title":"Arch Pharm Res"},{"key":"R24-20230924","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lfs.2018.10.060","article-title":"Homocysteine accelerates atherosclerosis via inhibiting lxr\u03b1-mediated ABCA1\/ABCG1-dependent cholesterol efflux from macrophages.","volume":"214","author":"Jin","year":"2018","journal-title":"Life Sci"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:04:42Z","timestamp":1695539082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000800","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}